DiaSorin SpA
Brad Sakowicz is a seasoned professional in the healthcare industry, currently serving as the Senior Director of Strategic Hospital Accounts at Diasorin since May 2025. Prior to this role, Brad held various leadership positions at Siemens Healthineers, Clear Labs, and Foundation Medicine, where responsibilities included regional sales management and directing commercial strategic initiatives. Brad's extensive experience in sales and business development is further underscored by positions at Ortho Clinical Diagnostics and Grifols, where significant accomplishments include exceeding sales targets and building long-term customer relationships. With a foundational education in nursing from the University of Cincinnati, Brad has received multiple recognitions for exceptional sales performance throughout a diverse career spanning over two decades.
This person is not in any teams
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.